2Standl E,Janka HU.High serum insulin conceratrations in relation toother cardiovascular risk factors in macrovasculag disease of type 2 diabetes[J].Horm M etab Res,1985,15(Suppl):46-51.
3Martin DB.Atherogenicity of insulin[J].Diabetes Res Clin Pratt,1988,4(Suppl):58,61.
4Feldman JM,Lebovitz HE.Appraisal of the extrapancreatic actions of sulfonylurcas[J].Arch Intem M ed,1969,123:314-322.
5Muller G,Satoh Y,Geisen K.Extrapancrcatic effects of sulphonylureas a comparison betw een glimepiride and conventional sulphonylureas[J].Diabetes Res Clin Pract,1995,28(Suppl):S115-S137.
6Johnson JL,Wolf SL,Kabadi UM.Efficacy of insulin and sulfonylurea combination therapy in type 2 diabetes:A meta-analysis of the randomized placebo-controlled trims[J].Arch Intern M ed,1996,156:259-264.
7Strowig SM,Pe-santa ML,Raskin P,et al.Comparison of insulin monotherapy and combination therapy w ith insulin and mefformin or insulin and troglimzone in type 2 diabetes[J].Diabetes Care,2002,25:2133-2140.
8Hatao K,Kaku K,Matsuda M,et al.Sulfonylurea stimulates liverfructoso-2,6-bisphosphate formation in proportion to its hypoglycemicaction[J].Diabetes Res Clin Pract,1985,1:49-53.
9Mori RC,Hirabaga SM,Hiram AE,et al.Glimepiride as insulin sensitizer:increased liver and muacle responses to insulin[J].Diabetes Obes Metab,2005,10(7):596-600.
10Dunseath G J,Atkinson M D,Owens D R.A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine:A single dose clamp study in people with type 2 diabetes[J].Diabetes&Metabolism,2013,39(6):537.
